In a report released on January 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Insmed (INSM – Research Report), with a ...

Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, ...

ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ...

Complete measurements of MSNA (measured by fibular nerve microneurography) resting supine brachial blood pressure (measured by automated oscillometry; BpTRU BPM-200), heart rate (measured via ECG), ...

Clinical question: Does inhaled amikacin reduce the incidence of ventilator-associated pneumonia (VAP) in critically ill patients? Background: VAP is a common and serious complication in patients on ...

Department of Environmental Health Sciences, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, California 90095, United States ...

ARIKAYCE ® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million— ...

This leaflet answers some common questions about DBL Amikacin Injection. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Hypersensitivity pneumonitis happens when you breathe in specific substances (allergens) that cause your body to have an allergic reaction. This is commonly an occupational disease that can be treated ...